

Company Focus

Syntopix is a specialised research and development business, focusing on **topical antimicrobial innovations** for products in consumer healthcare and pharmaceutical markets.

Having started with specific interests in **infection and acne**, the company is now able to apply its knowledge and expertise successfully to other commercial applications including oral care.

Following initial backing from the Wellcome Trust, Syntopix is now a quoted company on the Alternative Investment Market (ticker: SYN).

Approach & Opportunity

Our strategy of focusing on compounds and combinations of compounds with well-documented toxicity profiles and **established use in humans** offers an efficient route through discovery, pre-clinical and clinical development. This approach:

- Reduces risk
- Offers faster product development
- Decreases the cost of R&D

Having identified a growing pipeline of lead candidates, Syntopix has a bank of well characterised antimicrobial compounds and is now securing commercial agreements with **major consumer healthcare companies**.

Contact Us

Dr Stephen P. Jones
Chief Executive Officer
Syntopix Group plc
Institute of Pharmaceutical Innovation,
Bradford,
BD7 1DP
T 0845 125 9204 E spj@syntopix.com



World Class Scientific Expertise

Syntopix is a spin-out from the **world – renowned Skin Research Centre** at the University of Leeds. Formed in 2003, the company is based on the leading research of husband and wife team Drs Jon Cove and Anne Eady, both highly respected microbiologists. This scientific background is complemented by a panel of **highly regarded international experts** who advise the company on a regular basis and an experienced board of directors.

Product & Technology Pipeline

Our product and technology pipeline is generated through a rigorous process of bespoke antimicrobial screening which is informed by **extensive in-house expertise** and driven by potential for **rapid delivery** to the market. Syntopix has a growing library of over 1800 compounds.

The most advanced compounds are now entering the commercialisation phase and Syntopix is **actively seeking development partnership or licensee opportunities**.

Target	Compound	Research	Pre-Clinical	Clinical	Partnership Opportunity
Acne	SYN 0126				
Acne	SYN 0126 + 0091				
Acne	SYN 0126 + 0854 + 0040				
Acne	SYN 0126 + 0040				
Acne	SYN 1113				
Healthcare antimicrobial	SYN 0017				
Healthcare antimicrobial	SYN 0854				
Healthcare antimicrobial	SYN 0096				
Acne	SYN 1163				
Acne	SYN 1093				

Intellectual Property

The Syntopix Group IP portfolio comprises of more than 41 patent applications related to its lead compounds in key therapeutic areas. Pursuing a proactive strategy to protect and expand, our intellectual property is continually evolving and **covers all major global territories**.

www.syntopix.com

Syntopix
TOPICAL ANTIMICROBIAL INNOVATION